Compare FedEx Corporation (FDX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Tango Therapeutics Inc. — how do they compare? FedEx Corporation trades at $291.96 (market cap $68.77B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: FedEx Corporation is far larger — about 18.3× Tango Therapeutics Inc.'s market cap, and FedEx Corporation pays a 1.68% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Tango Therapeutics Inc. for 0 Days on average.
| FDX | TNGX | |
|---|---|---|
Market Cap | $68.77B | $3.75B |
Volume | 914,308 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $339.35 | $32.90 |
52-Week Low | $189.87 | $7.50 |
Typical Hold Time | 87 Days | 0 Days |
Enterprise Value | $98.41B | $2.77B |
Dividend Yield | 1.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $290.59, down 0.56% on the day, with a bearish technical signal and mixed oscillators. The company shows stable profitability with a net income margin of 4.68% and a P/E of 15.67, while recent earnings beats and a $300 million electric truck order from Harbinger highlight operational momentum. Cash flow trends indicate a projected rebound in 2026 to $7.8 billion net cash flow.
The outlook is cautiously optimistic, supported by analyst consensus favoring Buy ratings (57%) and a $307.55 price target. Key risks include exposure to fuel price volatility and competitive pressures, but strong institutional backing and dividend payments provide stability for long-term investors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
